Latest Risperdal Stories
Bernstein Liebhard LLP is representing numerous plaintiffs who have filed Risperdal lawsuits in the Pennsylvania litigation, all of whom allegedly developed gynecomastia (male breast growth) due
PHILADELPHIA, March 20, 2015 /PRNewswire/ -- A Philadelphia jury today affirmed by a 10-2 vote that Janssen Pharmaceuticals, a division of Johnson & Johnson, failed to warn of the risk to
The Firm is representing numerous plaintiffs who have filed Risperdal lawsuits in Pennsylvania that allege the antipsychotic medication caused gynecomastia, or male breast development.
The Firm is representing numerous clients in Risperdal lawsuits that have been filed in the Pennsylvania mass tort proceeding, all of whom allegedly developed gynecomastia due to treatment with
The Firm is currently representing numerous Risperdal lawsuit plaintiffs who raise similar questions regarding the tactics used to drive sales of the atypical antipsychotic medication.
Pharmaceutical manufacturer, Johnson & Johnson, loses $2.5 million verdict for marketing of Risperdal, a potent antipsychotic that caused female breast growth in a young boy the case revealed.
The Risperdal trial currently underway in the Pennsylvania mass tort, where Bernstein Liebhard LLP is actively filing claims, is the first to involve gynecomastia, and could provide insight into
The Firm is representing numerous gynecomastia plaintiffs who have Risperdal lawsuits pending in the same mass tort litigation.
The Firm is representing numerous clients in Risperdal lawsuits that allege gynecomastia in the Philadelphia Court of Common Pleas. New York, NY (PRWEB) February
Trial in Philadelphia involves allegations that Janssen Pharmaceuticals and parent company, Johnson & Johnson, failed to warn about the risks of male breast growth, a condition known as gynecomastia,
- a slit in a tire to drain away surface water and improve traction.